2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.04. Impact of STK11 and/or KEAP1 Deletion on Outcomes to Immunotherapy in Non-Small Cell Lung Cancer

Pdf Summary

This research presentation discusses the impact of STK11DEL and KEAP1DEL gene copy deletions on the outcomes of immunotherapy and chemotherapy in patients with non-small cell lung cancer (NSCLC). The study analyzed the response rates, progression-free survival, and overall survival of patients with KRASMUT advanced NSCLC who received immunotherapy alone. The study found that both STK11 and KEAP1 mutations are associated with a worse response to PD-L1 blockade in NSCLC, especially in patients with concurrent KRAS mutation. However, the effect of STK11 or KEAP1 gene copy deletion on the response to immunotherapy or chemotherapy is not well understood.<br /><br />The researchers analyzed clinicopathologic variables and treatment outcomes in patients with non-squamous NSCLC at the Dana-Farber Cancer Institute. They also performed multivariate analyses to account for various factors such as age, sex, smoking, performance status, treatment line, PD-L1 tumor proportion score, tumor mutational burden, and genetic mutations. The results showed that STK11 and KEAP1 gene copy deletions are generally associated with worse outcomes to immunotherapy and chemotherapy.<br /><br />The study also examined the impact of STK11 and KEAP1 gene copy deletions in all tumors, as well as their association with overall survival in a control group of NSCLC patients who were never treated with immunotherapy. Stratifying the results by KRAS status did not show any significant impact.<br /><br />Overall, the study suggests that STK11 and KEAP1 gene copy deletions have a negative impact on the outcomes of immunotherapy and chemotherapy in NSCLC patients. These findings highlight the importance of considering genetic mutations and copy deletions as biomarkers for treatment response and may help inform personalized treatment strategies for patients with NSCLC.

Asset Subtitle

Malini Gandhi, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, United States

Meta Tag

Speaker Malini Gandhi, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, United States

Topic Poster Listing

Keywords

STK11DEL

KEAP1DEL

gene copy deletions

immunotherapy

chemotherapy

non-small cell lung cancer

NSCLC

KRASMUT

PD-L1 blockade

clinicopathologic variables